Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Total Current Liabilities (2019 - 2026)

ADC Therapeutics has reported Total Current Liabilities over the past 8 years, most recently at $67.6 million for Q1 2026.

  • Quarterly results put Total Current Liabilities at $67.6 million for Q1 2026, up 17.02% from a year ago — trailing twelve months through Mar 2026 was $67.6 million (up 17.02% YoY), and the annual figure for FY2025 was $70.2 million, down 12.81%.
  • Total Current Liabilities reached $67.6 million in Q1 2026 per ADCT's latest filing, down from $70.2 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $87.6 million in Q3 2022 and bottomed at $49.3 million in Q4 2022.
  • Median Total Current Liabilities over the past 5 years was $67.7 million (2024), compared with a mean of $69.4 million.
  • The largest annual shift saw Total Current Liabilities surged 70.96% in 2022 before it fell 28.48% in 2024.
  • Over 5 years, Total Current Liabilities stood at $49.3 million in 2022, then soared by 37.31% to $67.7 million in 2023, then grew by 18.91% to $80.5 million in 2024, then dropped by 12.81% to $70.2 million in 2025, then dropped by 3.61% to $67.6 million in 2026.
  • Business Quant data shows Total Current Liabilities for ADCT at $67.6 million in Q1 2026, $70.2 million in Q4 2025, and $62.0 million in Q3 2025.